Consistent with this finding, CML mice treated with Zileuton, which reduces survival of CML LSCs by inhibiting the function of 5-lipoxygenase (the Alox5 gene product) [17], had a marked increase in bone marrow GFP+LSK− cells (Fig. 4C). The gene discussed is ALOX5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.